Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TNFSF8

TNFSF8

Basics

Aliases:
This biomarker is also known as:
  • CD30LG,
  • tumor necrosis factor ligand superfamily member 8,
  • CD30 antigen ligand,
  • CD30 ligand,
  • tumor necrosis factor (ligand) superfamily, member 8,
  • CD30L,
  • CD153,
  • CD30-L,
  • CD153 antigen,

View in BioMuta

Description…

TNFSF8, also known as CD30 ligand, is a cytokine belonging to the tumor necrosis factor (TNF) ligand family. TNFSF8 binds to TNFRSF8/CD30, a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. TNFSF8 has been shown to induce proliferation of T-cells. It also enhances cell proliferation of some lymphoma cell lines, and induces cell death and reduces cell proliferation of other lymphoma cell lines. There are two different isoforms encoded by two transcript variants.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: TNFSF8

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

TNFSF8 variants may be involved in the etiology of lung cancer.

Performance Comment

TNFSF8 is a member of the TNF ligand superfamily, which stimulates T-cell growth. Up-regulation of this protein correlates with proliferation in hematological malignancies. Further studies have shown possible involvement in susceptibility to lung cancer. TNFSF8 is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.